All studies
Rheumatology · Claims · Italy

Spini 2026

Psoriasis and psoriatic arthritis

ATSuperiorityAcademia, Government3/5 disclosures
Comparisons
2
In the analysis
2
all comparisons pooled
Target trials
1
Emulations reported
2
2 treatments

Comparisons

2 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
Serious infection by one year
vs EXCEED·RR·Safety
1.170.40–3.45
0.800.44–1.44
overlapPartial alignment-0.61 SE apart
Treatment discontinuation by one year
vs EXCEED·RR·Safety
0.610.45–0.81
0.790.74–0.85
overlapPartial alignment1.68 SE apart

Design and methods

Estimand
AT
Design hypothesis
Superiority
Matching / weighting
Propensity-score weighting
Analysis method
As-treated risk and survival models
Missing data
Complete case
DAG
No
QBA
No

Data and sample

Data type
Claims
Data sources
Distributed network
Geography
Italy
Eligible sample
8697
Treated
2256
Control
6441
Emulations
2
Treatments compared
2

Transparency

3/5
Protocol
No pre-registration
Preprint
No preprint
Data availability
Unavailable
Code availability
https://github.com/lubass82/VALORE_TTE
Conflicts of interest
Declared: Industry
COI institutions
Observational-study funding relationships listed in the report
Funding
Declared: Public
Funders
Italian public research support

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2026_Spini_Infection
DOI
10.1016/j.phrs.2026.108198
Affiliations
VALORE distributed database network and Italian academic institutions
Sector
Academia, Government
Target trials (study level)
EXCEED
Registration
NCT02745080